Examkin

Question

Difficulty: MediumGynecologic Infections

A 2424-year-old nulligravid woman comes to the clinic due to worsening lower abdominal pain and a new, foul-smelling vaginal discharge over the past 44 days. She has a copper intrauterine device (IUD) that was inserted three years ago. She recently became sexually active with a new male partner. Her temperature is 38.2∘C38.2^\circ\text{C} (100.8∘F100.8^\circ\text{F}), blood pressure is 118/76 mm Hg118/76\text{ mm Hg}, and pulse is 92/min92\text{/min}. Speculum examination shows a yellow, mucopurulent discharge exuding from the cervical os, and the IUD strings are clearly visible in the vaginal vault. Bimanual examination reveals pronounced cervical motion tenderness and bilateral adnexal tenderness. There are no palpable adnexal masses, and a pelvic ultrasound is unremarkable aside from a properly positioned intrauterine device. A urine pregnancy test is negative. Which of the following is the most appropriate next step in management?

  1. A
    Remove the intrauterine device and prescribe intramuscular ceftriaxone, oral doxycycline, and oral metronidazole
  2. B
    Leave the intrauterine device in place and prescribe intramuscular ceftriaxone and a single dose of oral azithromycin
  3. Leave the intrauterine device in place and prescribe intramuscular ceftriaxone, oral doxycycline, and oral metronidazoleAnswer
  4. D
    Remove the intrauterine device and admit the patient for intravenous cefoxitin and intravenous doxycycline
  5. E
    Leave the intrauterine device in place and prescribe oral ciprofloxacin and oral metronidazole

Answer

The most appropriate management is to leave the intrauterine device in place and treat the patient empirically with intramuscular ceftriaxone, oral doxycycline, and oral metronidazole.
This patient presents with classic signs of acute pelvic inflammatory disease (PID), including pelvic pain, fever, mucopurulent cervical discharge, and cervical motion tenderness. Because she is hemodynamically stable, non-pregnant, and without a tubo-ovarian abscess, she meets criteria for outpatient management. Current CDC guidelines recommend empiric outpatient treatment with a single dose of intramuscular ceftriaxone, supplemented by a 14-day course of oral doxycycline and oral metronidazole to adequately cover N. gonorrhoeae, C. trachomatis, and anaerobes. Furthermore, standard obstetric/gynecologic guidelines state that an existing intrauterine device (IUD) should be left in place when initiating treatment for acute PID. The IUD only requires removal if the patient demonstrates a lack of clinical improvement after 48 to 72 hours of appropriate antimicrobial therapy.

Step-by-Step Solution

1
Identify the clinical syndrome based on the patient's presentation.
The patient has fever, lower abdominal pain, mucopurulent cervicitis, cervical motion tenderness, and adnexal tenderness, meeting the clinical criteria for acute pelvic inflammatory disease (PID).
Recognizing the diagnostic criteria for PID is essential before selecting appropriate management.
2
Determine the appropriate setting for treatment (inpatient versus outpatient).
The patient is hemodynamically stable, is not pregnant, can tolerate oral medications, and lacks signs of a tubo-ovarian abscess; therefore, outpatient management is indicated.
Unnecessary hospital admissions should be avoided, and oral therapy is highly effective for mild-to-moderate PID.
3
Select the correct empiric antibiotic regimen for outpatient PID.
Guidelines dictate the use of intramuscular ceftriaxone combined with a 14-day course of oral doxycycline and oral metronidazole.
This combination ensures comprehensive coverage against Neisseria gonorrhoeae, Chlamydia trachomatis, and anaerobic vaginal flora.
4
Address the presence of the intrauterine device (IUD).
The IUD should be left in place while initiating antibiotic therapy.
Immediate removal is not required and has not been shown to improve outcomes in early PID. Removal is only indicated if the patient fails to improve clinically after 48 to 72 hours of appropriate therapy.

Key Concept

Outpatient management of mild-to-moderate pelvic inflammatory disease requires empiric coverage with intramuscular ceftriaxone, oral doxycycline, and oral metronidazole; an intrauterine device should initially be left in place.
Estimated Time:1m 15s
Rate this question

Topics

Gynecologic Infections

More questions from this topic